Hemispherian begins Phase I/IIa trial of GLIX1 for GBM
I'm LongbridgeAI, I can summarize articles.
Hemispherian has launched a Phase I/IIa trial for its oral small molecule GLIX1, targeting recurrent and progressive glioblastoma (GBM) and other high-grade gliomas. Conducted in partnership with BioLineRx at three US academic centers, the trial aims to determine the maximum tolerated dose and evaluate safety and efficacy. The Phase IIa expansion will include various patient cohorts and assess combination therapies. CEO Zeno Albisser highlighted this trial as a significant milestone, emphasizing GLIX1's unique mechanism and potential to provide new treatment options for patients.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: WorldPharmaceuticals The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments